OPKO Health (NASDAQ:OPK – Get Free Report) and HCA Healthcare (NYSE:HCA – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, profitability and analyst recommendations.
Valuation & Earnings
This table compares OPKO Health and HCA Healthcare”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OPKO Health | $606.90 million | 2.02 | -$225.68 million | ($0.09) | -18.22 |
| HCA Healthcare | $75.60 billion | 1.16 | $6.78 billion | $29.87 | 13.56 |
Profitability
This table compares OPKO Health and HCA Healthcare’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OPKO Health | -12.40% | -5.88% | -3.83% |
| HCA Healthcare | 8.77% | -244.79% | 11.10% |
Risk & Volatility
OPKO Health has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, HCA Healthcare has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.
Insider & Institutional Ownership
64.6% of OPKO Health shares are held by institutional investors. Comparatively, 62.7% of HCA Healthcare shares are held by institutional investors. 44.7% of OPKO Health shares are held by insiders. Comparatively, 1.5% of HCA Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for OPKO Health and HCA Healthcare, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OPKO Health | 1 | 3 | 1 | 0 | 2.00 |
| HCA Healthcare | 1 | 8 | 14 | 0 | 2.57 |
OPKO Health currently has a consensus target price of $1.55, indicating a potential downside of 5.49%. HCA Healthcare has a consensus target price of $462.64, indicating a potential upside of 14.25%. Given HCA Healthcare’s stronger consensus rating and higher probable upside, analysts plainly believe HCA Healthcare is more favorable than OPKO Health.
Summary
HCA Healthcare beats OPKO Health on 9 of the 14 factors compared between the two stocks.
About OPKO Health
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
About HCA Healthcare
HCA Healthcare, Inc., through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, it operates behavioral hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.
